Brought to you by 
Advent Venture seeds Alzheimer’s start-up CoCo Therapeutics
27 Mar 2013
Executive Summary
CoCo Therapeutics Ltd., which will research the role of the nuclear receptor, retinoic acid receptor (RAR), in Alzheimer’s disease, has received an undisclosed amount of seed funding from Advent Venture Partners. An Advent general partner joined CoCo’s board as chairman.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advent Venture seeds Alzheimer’s start-up CoCo Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice